...
首页> 外文期刊>International Journal of Medical Sciences >Risk Factors for Oxaliplatin-Induced Hypersensitivity Reactions in Japanese Patients with Advanced Colorectal Cancer
【24h】

Risk Factors for Oxaliplatin-Induced Hypersensitivity Reactions in Japanese Patients with Advanced Colorectal Cancer

机译:日本晚期大肠癌患者中奥沙利铂引起的超敏反应的危险因素

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: Previously, we suggested that oxaliplatin (L-OHP)-related grade 3/4 hypersensitivity reactions occurred immediately after the initiation, but grade 1/2 reactions did not. This study was conducted to clarify the risk factors for L-OHP-related hypersensitivity reactions. Methods: Clinical data from 108 Japanese patients with colorectal cancer were analyzed, who were treated with L-OHP-containing regimens, FOLFOX4 and/or mFOLFOX6. The risk factors examined included demographic data, preexisting allergies, laboratory test data, treatment regimen, treatment line of therapy, pretreatment with steroids, total number of cycles and cumulative amount of L-OHP. Results: The incidence of grade 1/2 and grade 3/4 hypersensitivity reactions were found at 13.0% (14/108) and 9.3% (10/108), respectively. Female (P=0.037), preexisting allergies (P=0.004) and lower level of lactate dehydrogenase (P=0.003) were risk factors for grade 1/2 hypersensitivity reactions, and higher neutrophil count (P=0.043) and lower monocyte count (P=0.007) were for grade 3/4 reactions. Total number of cycles were larger in the patients with grade 3/4 reactions than those without reactions (P=0.049). Conclusions: Further extensive examination with a large number of patients is needed to establish a patient management strategy.
机译:目的:以前,我们建议与奥沙利铂(L-OHP)相关的3/4级超敏反应在开始后立即发生,而1/2级反应则没有。进行这项研究是为了阐明与L-OHP相关的超敏反应的危险因素。方法:分析了108例日本大肠癌患者的临床资料,这些患者接受了含L-OHP方案,FOLFOX4和/或mFOLFOX6的治疗。检查的风险因素包括人口统计学数据,既往过敏,实验室测试数据,治疗方案,治疗的治疗方案,类固醇的预处理,周期总数和L-OHP的累积量。结果:1/2级和3/4级超敏反应的发生率分别为13.0%(14/108)和9.3%(10/108)。女性(P = 0.037),既往过敏(P = 0.004)和较低水平的乳酸脱氢酶(P = 0.003)是1/2级超敏反应的危险因素,中性粒细胞计数较高(P = 0.043)和单核细胞计数较低( P = 0.007)用于3/4级反应。有3/4级反应的患者的总周期数比无反应的患者大(P = 0.049)。结论:需要对大量患者进行进一步的广泛检查,以建立患者管理策略。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号